
Chimerix places its bets on Oncoceutics' dopamine antagonist for rare brain cancer in quest to salvage its image
In the clinical wasteland of aggressive brain cancers, Philly’s Oncoceutics has churned out promising data with a Phase II candidate on the verge of an FDA filing. Chimerix, looking to turn around its reputation — and share price — has jumped on board, putting half-a-billion-dollar hopes in Oncoceutics’ drug.
Chimerix will acquire private biotech Oncoceutics and lead candidate ONC-201, an oral small molecule dopamine receptor D2 antagonist and caseinolytic protease agonist currently being tested in a Phase II trial against recurrent glioma, a form of brain cancer with a particularly poor prognosis, the companies said Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.